Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100

S M Skevington, A Wright

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background The study arises from the need for good quality of life (QOL) assessment and a new comprehensive generic QOL profile for cross-cultural use. Aims To examine changes in the QOL of patients receiving antidepressants from a general practitioner, and to assess the validity and sensitivity of a new QOL measure. the World Health Organization Quality of Lire Assessment (I GO-item version) (WHOQOL-100). Method Patients with moderate depression (n=106) completed the WHOQOL-100 and Beck Depression inventory at the start of treatment and again after 6 weeks. Results Depression decreased significantly over 2 months and 74% reported feeling better. WHOQOL-100 scores increased in 24 of the 25 facets, demonstrating that QOL improves significantly in the 8 weeks following the start of antidepressant treatment. It also shows the instrument's validity and sensitivity to changes in clinical condition. Conclusions The UKWHOQOL-100 is confirmed as excellent to good. Antidepressants significantly and comprehensively improve QOL. Declaration of interest The research was funded by Glaxo-Wellcome Research & Development (Pharmacoeconomics) (RESA 1040).
Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalThe British Journal of Psychiatry
Volume178
Issue number3
Publication statusPublished - 2001

Fingerprint

Antidepressive Agents
Primary Health Care
Quality of Life
Depression
Pharmaceutical Economics
Research
General Practitioners
Emotions
Equipment and Supplies
Therapeutics

Cite this

Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100. / Skevington, S M; Wright, A.

In: The British Journal of Psychiatry, Vol. 178, No. 3, 2001, p. 261-267.

Research output: Contribution to journalArticle

@article{2470240e7fa14d27b2fb675c97cc3806,
title = "Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100",
abstract = "Background The study arises from the need for good quality of life (QOL) assessment and a new comprehensive generic QOL profile for cross-cultural use. Aims To examine changes in the QOL of patients receiving antidepressants from a general practitioner, and to assess the validity and sensitivity of a new QOL measure. the World Health Organization Quality of Lire Assessment (I GO-item version) (WHOQOL-100). Method Patients with moderate depression (n=106) completed the WHOQOL-100 and Beck Depression inventory at the start of treatment and again after 6 weeks. Results Depression decreased significantly over 2 months and 74{\%} reported feeling better. WHOQOL-100 scores increased in 24 of the 25 facets, demonstrating that QOL improves significantly in the 8 weeks following the start of antidepressant treatment. It also shows the instrument's validity and sensitivity to changes in clinical condition. Conclusions The UKWHOQOL-100 is confirmed as excellent to good. Antidepressants significantly and comprehensively improve QOL. Declaration of interest The research was funded by Glaxo-Wellcome Research & Development (Pharmacoeconomics) (RESA 1040).",
author = "Skevington, {S M} and A Wright",
note = "ID number: ISI:000167244700013",
year = "2001",
language = "English",
volume = "178",
pages = "261--267",
journal = "The British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "3",

}

TY - JOUR

T1 - Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100

AU - Skevington, S M

AU - Wright, A

N1 - ID number: ISI:000167244700013

PY - 2001

Y1 - 2001

N2 - Background The study arises from the need for good quality of life (QOL) assessment and a new comprehensive generic QOL profile for cross-cultural use. Aims To examine changes in the QOL of patients receiving antidepressants from a general practitioner, and to assess the validity and sensitivity of a new QOL measure. the World Health Organization Quality of Lire Assessment (I GO-item version) (WHOQOL-100). Method Patients with moderate depression (n=106) completed the WHOQOL-100 and Beck Depression inventory at the start of treatment and again after 6 weeks. Results Depression decreased significantly over 2 months and 74% reported feeling better. WHOQOL-100 scores increased in 24 of the 25 facets, demonstrating that QOL improves significantly in the 8 weeks following the start of antidepressant treatment. It also shows the instrument's validity and sensitivity to changes in clinical condition. Conclusions The UKWHOQOL-100 is confirmed as excellent to good. Antidepressants significantly and comprehensively improve QOL. Declaration of interest The research was funded by Glaxo-Wellcome Research & Development (Pharmacoeconomics) (RESA 1040).

AB - Background The study arises from the need for good quality of life (QOL) assessment and a new comprehensive generic QOL profile for cross-cultural use. Aims To examine changes in the QOL of patients receiving antidepressants from a general practitioner, and to assess the validity and sensitivity of a new QOL measure. the World Health Organization Quality of Lire Assessment (I GO-item version) (WHOQOL-100). Method Patients with moderate depression (n=106) completed the WHOQOL-100 and Beck Depression inventory at the start of treatment and again after 6 weeks. Results Depression decreased significantly over 2 months and 74% reported feeling better. WHOQOL-100 scores increased in 24 of the 25 facets, demonstrating that QOL improves significantly in the 8 weeks following the start of antidepressant treatment. It also shows the instrument's validity and sensitivity to changes in clinical condition. Conclusions The UKWHOQOL-100 is confirmed as excellent to good. Antidepressants significantly and comprehensively improve QOL. Declaration of interest The research was funded by Glaxo-Wellcome Research & Development (Pharmacoeconomics) (RESA 1040).

UR - http://bjp.rcpsych.org/cgi/content/abstract/178/3/261

M3 - Article

VL - 178

SP - 261

EP - 267

JO - The British Journal of Psychiatry

JF - The British Journal of Psychiatry

SN - 0007-1250

IS - 3

ER -